AccuraGen
AccuraGen uniquely employs rolling-circle amplification to perform consensus-based concatemer error correction. The fundamental of our technology ensures a high conversion rate and minimizes the proliferations of errors. We optimized our assay to detect a breadth of genetic alterations with a sensitivity approaching the physical limit and a specificity as much as 100x better than benchmark.
Last updated on
About AccuraGen
Founded
2013Estimated Revenue
$1M-$10MEmployees
11-50Funding / Mkt. Cap
$40MCategory
Sector
Health CareIndustry Group
Pharmaceuticals, Biotechnology & Life SciencesIndustry
BiotechnologyLocation
City
Menlo ParkState
CaliforniaCountry
United StatesAccuraGen
Find your buyer within AccuraGen